Radical hysterectomy with pelvic lymphadenectomy has been regarded as the optimal surgical approach in managing early invasive cervix cancer. Pelvic lymphadenectomy has not been shown to improve prognosis in node positive patients and is probably unnecessary in patients with negative nodes. Wide parametrial excision has considerable morbidity. We report a retrospective analysis of surgically managed early stage disease the aims of which were: to define the incidence of parametrial tumour extension and to assess the therapeutic benefit of wide parametrial excision.
The case records and pathology reports of 141 patients who underwent radical hysterectomy with pelvic lymphadenectomy between 1980 and 1987 were reviewed (median follow-up 32 months). Nine (6.3%) had direct tumour extension into the parametrium (5 with positive and 4 with negative nodes). Four of five node positive patients received post operative external beam radiotherapy (EBRT) and three have relapsed (2 with pelvic and distant and 1 with only distant recurrence). In the four node negative patients 2 received post operative EBRT and one has relapsed with pelvic disease. Twenty of the remaining 132 patients were node positive and 112 were node negative. Thirteen with positive nodes received EBRT and three have relapsed (1 with pelvic and 2 with pelvic and distant recurrence). Three of the remaining seven node positive patients have relapsed (2 with pelvic and 1 with pelvic and distant recurrence). Fifteen node negative patients have relapsed (9 with pelvic, 3 with pelvic and distant and 3 with distant recurrence alone). There was no signifiant difference in relapse rate between patients with positive nodes who did or did not receive post operative EBRT. The only patients who can be regarded as benefiting from wide parametrial excision are those with direct tumour extension to the parametrium who have negative nodes and do not subsequently relapse, i.e. three of 141 patients (2.1%). These data do not support the hypothesis that wide parametrial excision is of therapeutic benefit and question the value of post operative pelvic radiotherapy. There may be potential for management of small volume early stage disease by simple hysterectomy followed by adjuvant therapy where tumour spread to the parametrium or pelvic nodes is found to have occurred. disease were treated with cyclophosphamide (1 g m-2). There was no cross over between the two arms of the study.
The response rates were 62% for JM8 and 36% for JM9. Sixteen patients were unevaluable for response. The median survival is 96 weeks for JM8 patients and 68 weeks for JM9 patients (P=0.1319). The amount of residual disease after initial laparotomy was a prognostic factor for survival. Myelosuppression was the main toxicity and was greater with JM9.
The study shows JM8 to be more active than JM9 in the treatment of ovarian cancer Thirty-six patients with ovarian cancer were treated with intraperitoneal 131 I labelled monoclonal antibodies. The activity of 1311 administered was increased from 20mCi to 158 mCi and toxicity and efficacy evaluated. Detailed pharmacokinetic studies were undertaken in 11 patients and compared to those of five retreated patients who had developed antibodies against the mouse immunoglobulin. Patients receiving their first treatment had a maximum of 25% (range 19.8-39 .8%) of the injected activity in their circulation. This was accompanied by marrow suppression at 1311 activities over 120mCi. The five retreated patients had only 5% of the injected activity in their circulation (range 3.8-6%), with rapid urinary excretion and negligible marrow suppression.
In the 31 patients with assessable disease there was no response in eight patients with gross disease (nodules > 2 cm), a partial response in 2 out of 15 patients with nodules <2 cm, and complete response in three out of 6 patients with microscopic residual disease. The non-specific radiation dose to the peritoneal serosa was measured by lithium fluoride thermoluminescent radiation dosimetry in 11 patients. The dose received by the peritoneal serosa was less than 500 cGy.
It is concluded that i.p. 1311 labelled antibodies may be effective against very small tumour deposits. The local radiation dose to the normal peritoneal serosa is low due to the efficient systemic absorption of antibody. Bone marrow suppression is the dose limiting factor. This may be reduced by administering concurrent systemic anti-mouse immunoglobulin. (hCG) preparations from the urine of pregnant females. We treated 39 patients with advanced ovarian cancer (FIGO stage III or IV) who had relapsed following conventional treatment. The D-Trp-6-LHRH microcapsules were administered once a month. There were no exclusion criteria and patients of any age or performance status were eligible. Six patients achieved a partial remission where the tumour decreased in volume more than 50%. The responses were maintained for a mean duration of 10 months (range 6-18 months). Twenty-eight patients continued to have progressive disease and 25 died within the first 16 weeks from the start of therapy reflecting the poor performance status of these patients. Five patients remained stable on D-Trp-6-LHRH for varying periods from 3-12 months. The responding patients had a significantly longer survival than nonresponding patients. Therefore, 11 patients (6PR + 5SD) have had remission or stabilization of disease which has been clinically worthwhile. This clinical benefit with slow-release D-Trp-6-LHRH in -27% of patients is highly encouraging and offers an important non-toxic alternative in patients who are either intolerant of chemotherapy or in those patients who have progressive disease following chemotherapy.
D-TRP-6-LHRH (decapeptyl)
:
Head and Neck Cancer
Production of transforming growth factors alpha and beta by oral squamous cell carcinoma, human skin and cultured keratinocytes M. Partridge
Charing Cross Sunley Research Centre, London and Unilever Research, Sharnbrook, Bedford, UK.
There is evidence for normal and abnormal growth control mechanisms involving growth promoting and inhibiting factors. We have examined a series of oral squamous cell carcinomas (SCC), skin and cultured keratinocytes for the production of transforming growth factor alpha (TGFax), transforming growth factor beta (TGF#) and in some cases for the presence of epidermal growth factor receptor (EGFR) . The experiments were designed to investigate whether these factors are produced locally in tissues and hence potentially play a role in normal and malignant cell growth.
Using northern blotting and radioimmunoassay we detected TGFa and # in normal skin and cultured keratinocytes. Addition of EGF to cultured keratinocytes resulted in increased secretion of TGFoa and # suggesting that production of these factors may be regulated by exogenous growth factors. We find a relationship between the presence of TGFa and its receptor (EGFR) in oral SCC which also suggests an autocrine loop influencing growth of these tumours. An inverse correlation between the level of TGFa detected and EGFR expression was observed. This may be explained by proposing active metabolism and degradation of TGFa via the EGFR in SCC. TGFfl was also detected in these tumours but evidence suggests that the tumour may be unable to respond to the inhibitory effects of this ligand (Ozanne et al., J. Pathol., 149, 9, 1986) . This lack of normal inhibitory regulatory control may be related to continued tumour growth. The administration of bromodeoxyuridine with delayed tumour sampling has given cell kinetic data in 75 human tumours. Conventional views on the rate of growth of human tumours, based on histopathology, must be revised in a number of tumours in the light of this new knowledge.
Verrucal carcinoma is generally regarded as a slowly growing tumour and one difficult to cure by radiotherapy. Four cases will be described where cell kinetic studies have been performed. In all four, cell cycle times were remarkably short indicating that there was a potential for rapid cellular proliferation. This can be contrasted with the apparently slow rate of increase in size associated with such a tumour. Three of these patients were treated by a regime of continuous, hyperfractionated, accelerated radiotherapy in which 36 fractions were given over a period of 12 days (CHART). All have shown a complete regression of tumour. The final case was treated by surgery. A wide range of head and neck tumours have been treated with the CHART regime and results showed significant improvement when comparison was made with previously treated cases. Cell kinetic studies performed in many of these tumours showed that in most there was a capacity for rapid repopulation. Such a capacity is likely to be expressed once cell destruction occurs on initiation of treatment. Cell kinetic data are likely to be a major influence in the programming of cancer treatment.
A controlled prospective randomised trial of combination chemotherapy administered synchronously or sequentially with radical radiotherapy: An analysis of prognostic factors in advanced squamous carcinoma of the head and neck
F.M.B. Calman
On behalf of the SECOG Trial Steering Committee, UK.
Between February 1980 and June 1986, 361 patients with advanced (Stages III and IV) squamous cancer of the head and neck were randomised into a trial comparing combination chemotherapy (vincristine, bleomycin and methotrexate) given either synchronously or sequentially with radical radiotherapy. A further randomisation was made between the addition of 5-fluoro-uracil and no 5-fluoro-uracil in a 2-by-2 factorial design. There was no significant difference between the two arms of the trial although patients receiving 5-FU had improved disease-free survival compared with those who did not (P=0.05). The results of the study have been analysed by disease site, extent of primary tumour (T), nodal status (N), age, sex and degree of differentiation of tumour. Nodal status was the most significant prognostic factor in patients with advanced disease. One hundred and twenty-six patients have undergone salvage surgery following primary treatment with chemotherapy and radiotherapy for stage 3 or 4 squamous carcinoma of the head and neck. The SECOG trial design and 5 year survival data on 429 patients entered is itemised by primary site and chemotherapy arm.
Surgery was limited to histologically proved persisting or recurrent carcinoma. Fifty-four patients received synchronous, and 72 received sequential treatment using VBM or VBMF with full dose megavoltage radiotherapy.
Details of primary site, TNM status, allocated treatment and results of surgery in all 126 patients are itemised. Five year postoperative survival is 33% and a highly significant trend (P=0.002) in favour of the older patients is reported.
The range of surgical excision and reconstruction carried out with early postoperative mortality is itemised for this prospective study maintaining complete follow up. ORN. Twelve patients with ORN defined as 'an area of exposed mandible in a previously irradiated field that fails to heal for two months' underwent corrective surgery. Bone was debrided until bleeding trabeculae were encountered, and in some cases the residual mandible was covered with local vascularised flaps. The bone removed was collected in plain sterile pots, and jars of Robertson's cooked meat medium. It was then cultured on neomycin blood agar for anaerobic bacteria and Actinomyces species, and on Sabouraud's medium for Candida species, in addition to routine culture on blood agar.
A mixed growth of mouth flora was cultured from the bone in eight cases, Candida species in three cases and Actinomyces species were not isolated despite prolonged anaerobic culture. Soft tissue specimens grew Staphylococcus aureus in three cases, Group G Streptococcus in one case, and anaerobes in one case. Histology specimens showed no permeation of the medulla with microorganisms.
Our results suggest that ORN is not primarily an infective osteomyelitis in which bone destruction progresses rapidly through the medullary cavity, although microorganisms are present. This has important implications for the management of ORN. Single fraction radiotherapy using superficial X-ray machine has obvious advantages in the treatment of small superficial carcinomas of the skin. We have studied retrospectively 1,005 cases of basal cell carcinoma and squamous cell carcinoma of the skin, treated by a single fraction X-ray therapy in 1976 in this institution to define the tumour recurrence and late radiation necrosis rates with treatment using different radiation doses and different field sizes.
Three radiation doses were used: 22.5 Gy, 20 Gy and 18 Gy. All cases were treated by superficial X-ray machine at 45kV or 100kV (10cm FSD). The cumulative recurrence rate after 10 years of follow-up was 4.4%. The cumulative late radiation necrosis rate was 6% (17% required surgical repair). The relationship between field sizes/radiation dosages and recurrence/necrosis rates were as follows:
Diameter of radiation portal (cm) 1.5-2.0 2.1-3.0 3.1-4.0 4.1-5.0 (N=531) (N= 415) There are no histological features which predict the biological behaviour of pre-malignant and pre-invasive breast lesions increasingly detected as a result of breast screening. We have investigated changes in cellular DNA content, proliferation index (PI) and ploidy during the evolution of carcinogen induced rat mammary carcinoma.
Following intragastric installation of dimethylbenzanthracene, or saline as control, breast tissue was sampled at 2-weekly intervals, disaggregated, feulgen stained and PI and ploidy assessed using integrating microdensitometry.
Glandular hyperplasia present in 45% of glands was seen more frequently than in controls by the second week of treatment (P<0.01). Mean PIs of 7 and 9% were significantly higher in induced breast at 2 and 4 weeks relative to control values of 4.6 and 3.7% (P<0.04 and P<0.03 respectively). Aneuploid profiles, never seen in controls, first occurred at 4 weeks in 33% of glands, rising to a maximum of 54% by 6 weeks. Carcinoma, evident at 6 weeks, occurred in up to 50% of glands, but was preceded by aneuploidy and abnormally high PI in all cases (r=0.86; P<0.05 and r=0.98, P<0.01 respectively).
In this animal model quantitative changes in cellular DNA content precede the appearance of carcinoma, indicating the potential benefit of similar assessment of human pre-invasive breast lesions. For some years it has been considered that radioresponsiveness of tumour cells is closely related to their recovery proficiency. More recently, on the basis of studies in murine systems, it has been suggested that the level of induced damage, rather than differences in its repair, may be important (Radford, 1986) .
We have therefore set out to analyse the extent to which the level of damage induced by irradiation correlates with radiosensitivity in a wide range of human tumours. Nine tumours of differing radiosensitivity were investigated. DNA damage, as double strand breaks (dsb) was measured using neutral filter elution immediately after irradiation at ice temperature and compared with cellular survival obtained by soft agar and monolayer colony forming assays.
The slope of the dsb-induction curve reflected the shape of the corresponding survival curve, with two distinct patterns being seen. In the five most sensitive lines (mean survival at 2Gy, 0.3) dsb induction was linear with dose. In the four more resistant lines (mean survival at 2Gy, 0.6) dsb induction was biphasic with an initial shoulder. Between the groups a two-fold difference in dose was required to produce the same DNA damage at doses within the survival range.
These data suggest that differences in radiosensitivity are related to differences in damage induction, without the need to postulate differences in repair capacity. Many models have been proposed to explain the relationship between dose of low LET radiation and cell survival. Most of these have utilised hypothetical concepts such as specific intracellular targets for which there is no firm biological basis. The Chadwick-Leenhouts model does have a biological basis of single and double strand DNA breaks, but only fits the infrequent situation of a continuously curving cell survival function.
We propose an alternative model which relates reproductive death of cells by radiation to loss of chromatin at cell division. This loss of chromatin can occur through chromosomal deletions or through the formation of asymmetrical chromosomal exchanges. It is proposed that smaller doses of radiation produce fewer chromatin breaks, which are more likely to be accurately repaired, compared to larger doses. Consequently, smaller doses of radiation are less efficient in causing cell death, leading to a shoulder on the cell survival curve. Much experimental evidence is in support of this model, and the fit between the derived formula described in this paper and experimental cell survival curves is good. The derived formula approximates to the linearquadratic equation at low doses of radiation. One hundred and twenty-eight previously untreated patients with metastatic testicular teratoma have been given BEP chemotherapy (cisplatinum 20 mg m-2 days 1-5, etoposide 120 mgm-2 days 1-3, bleomycin 30mg days 2, 9, 16) between 1979 and 1986. Mean follow up from commencement of treatment is 51 months (range 14 m-84m). The Royal Marsden Hospital staging system was used and patients divided into prognostic groups as defined by the MRC working party (Lancet, 1985) . Ninety cases had small volume (15 with high markers), 22 cases large volume (10 with high markers) and 16 very large volume disease (10 with high markers).
Disease free/survival results are for small volume disease, 94%/99%; large volume disease 73%/73%; very large volume disease 25%/31%. Residual masses were resected in 50 patients. White count nadir <1,000 mm-3 occurred in 3%, platelet nadir <50,000mm-3 in 2% and Hb <9.5g 100ml-1 in 15% of 482 chemotherapy courses. Septicaemia occurred in 4 patients with 1 fatality. Symptomatic bleomycin lung damage was reported in 22 patients. Steroid treatment was necessary in only 4 cases, with one death. Mean fall in EDTA renal clearance after 4 courses of chemotherapy was 26mlmin-' (range +78 to -81mlmin-1).
Twenty-four pregnancies have produced 21 normal offspring.
The identification of risk related factors has enabled the design of chemotherapy regimes of reduced toxicity in good prognostic groups, whilst intensifying treatment in high risk cases. This series will permit future comparison with such sequential studies. Group' Between April 1986 and May 1987, 562 patients were recruited from ten countries into a multicentre, randomised trial comparing 'zoladex' with a combination of 'zoladex' and the nonsteroidal antiandrogen flutamide. 'Zoladex' was administered as a depot injection every 28 days and flutamide was given as three 250mg tablets daily.
Patients with histologically confirmed locally advanced (T3/T4) or metastatic (M 1) carcinoma were included. Previous hormone therapy, anti-hormone therapy, chemotherapy or patients having had an orchidectomy were excluded.
Fifty-five percent of the patients had Ml disease, the remaining being locally advanced disease. The two groups were balanced between major demographic parameters (T category, histology, metastases, performance status, etc.).
The median duration of follow up is 34 weeks in the zoladex group and 28 weeks in the combined treatment group.
The objective and subjective response rates are similar in both groups, but the median time to treatment failure is significantly longer in the zoladex group, largely due to the greater number of withdrawals because of the adverse reaction from the combined treatment (P=0.004). A pilot study was performed to define the acute toxicity of AF in the radical treatment of bladder cancer. Treatment was in 2 phases, treating the bladder to 60-64Gy in 30-32 fractions over 4 weeks and the upper pelvic nodes to 44Gy in 22 fractions over 4 weeks. The schedule employed 2 fractions per day on 16 treatment days, with a minimum of a 6 hour gap between fractions. Of 16 patients entering the study, 15 completed radiotherapy according to protocol. One developed subacute bowel obstruction after 44 Gy, which was managed conservatively. The pattern of toxicity in the other patients was as follows: Mild diarrhoea in 11/15 (73%) typically lasting 3 or 4 days in the 2nd week of treatment and 7-10 days following completion; frequency of micturition with nocturia > x 5 in 10/15 (67%) and dysuria in 7/15 (47%) appeared during the 4th week and lasted 1-2 weeks after the end of treatment. The only non-transient toxic reaction has been in a further patient who had relatively mild side effects during radiotherapy but who developed subacute bowel obstruction 2 months later, which was treated by defunctioning colostomy. The median follow up following AF is 6 months and it is too soon to define late side effects, though none have yet been seen.
It seems likely that AF is associated with increased acute reactions but the schedule of 64 Gy in 32 fractions in 4 weeks was tolerated by most patients, and should be investigated in a prospective randomised trial. One hundred and eight patients (previously untreated with chemotherapy and having bidimensionally measurable metastatic urothelial malignancy) have been entered into sequential chemotherapy trials between 1977 and 1988. Complete response occurred in 1 of 23 receiving methotrexate (M), 0 of 15 receiving cisplatin (P), 0 of 20 receiving carboplatin, 3 of 20 receiving M + P, 5 of 12 receiving M + vinblastine + P, and 2 of 8 receiving M + V + adriamycin + P. Overall complete plus partial response rate was higher in the M +P, MVP and MVAC groups (75%), though so was toxicity with 35% of patients experiencing temporary major renal failure episodes. Although WHO/UICC performance status 3 and 4 patients had a lower incidence and shorter duration of response, it did not provide a means of excluding patients who achieved complete remission.
Studies using serial urine cytology showed that 7 of 14 responders had complete loss of malignant cells from the urine compared to none of 21 non-responders and there was a suggestion that duration of overall clinical response was longer in those showing a cytological response. Another factor influencing response was expression of BhCG. Elevated serum levels of BhCG were found in 1 of 18 TlMO, 0 of 23 T2,3,4 MO, 0 of 4 TxNI-4M0, and 9 of 12 TxNxMl tumours. None of 9 who were BhCG positive N x Ml patients responded to chemotherapy, in contrast to 3 of 4 with BhCG negative lymphnode metastases and 2 of 3 with BhCG negative distant metastases. In NWTS-3, patients with stage II favourable histology (FH) tumours were randomized to receive either no radiotherapy (RT) or 2,000cGy to the tumour bed postoperatively. Stage II FH children were randomized between 1,000 cGy and 2,000cGy. RT boosts were allowable but given to only 6 of 280 (2%) stage III and none of the 280 stage II patients. For both stages there was also a chemotherapy (CT) randomization to either intensified actinomycin D (AMD) plus vincristine (VCR) or to less intensive AMD plus VCR plus doxorubicin (ADR). No statistically significant differences were noted for abdominal relapses or disease-free survival between any RT set. Stage III patients treated with three drugs had a borderline statistical advantage for disease-free survival (P= 0.06). We conclude that 1,000cGy is enough for stage III patients if three drugs are used.
Haematological Neoplasia and Sarcomas
The BNLI study of Previous BNLI studies in advanced Hodgkin's disease have shown: (1) MOPP is more effective than MOP (prednisone omitted), (2) addition of bleomycin to MOPP is of no benefit, (3) maintenance with CCNU (lomustine), vinblastine and bleomycin is of no benefit and (4) LOPP (leukeran substituted for mustine) is as effective yet much less toxic than MOPP.
In the current study in advanced Hodgkin's disease started in June 1983, patients are randomised to LOPP or LOPP alternating with EVAP (etoposide, vinblastine, adriamycin, prednisolone) . Over 400 patients have been entered so far; 317 are included in this analysis. The CR rate is better for LOPP/EVAP than for LOPP (69 and 60% respectively) as is the actuarial percentage disease-free survival at two years (60 and 44% respectively; P<0.05). This advantage in favour of the alternating regimen does not appear to be due to a lower frequency of poor prognostic factors in this arm compared to the LOPP arm. The difference was maintained for other acknowledged individual prognostic factors. At present there is no survival advantage from the alternating treatment (84% overall survival at 2 years in both arms). Apart from an increased infection rate associated with more severe and unpredictable myelosuppression, and invariable alopecia, the LOPP/EVAP regimen has been well tolerated by most patients. Treatment of patients with resistant myeloma is often difficult because age and physical condition often restricts their ability to tolerate more intensive chemotherapeutic regimens. We describe our experience of hemi-body irradiation [HBI] in 41 patients with resistant multiple myeloma.
Hemi-body irradiation
Patients were staged using the MRC prognostic criteria: 2 patients were in group I, 18 patients in group II and 21 patients in group III. Age and sex distribution were similar in each group. Each group had received similar amounts of chemotherapy prior to HBI (median 8 courses of melphalan and prednisolone), 10 patients had also failed second line chemotherapy. Twenty-three patients had previously received local radiotherapy. Hemi-body irradiation was administered using a single fraction cobalt source at a dose rate of 0.25Gymin-i at median doses of 7.5Gy (upper half) and 9 Gy (lower half) with a median interval of 9 weeks in those receiving double HBI. Seventeen patients had double HBI, only 1 patient in whom a second treatment was planned refused it and 3 deteriorated before it could be carried out.
Twenty The formation of new blood vessels is important to the growth of most solid cancers. However, histological sections reveal little about the mechanisms of neovascularisation and experimental models have been limited by the lack of a precise and reliable endothelial cell marker. Evaluation of tumour induced vascular growth is often qualitative and subjective. A new method of studying angiogenesis is described.
In SWR mice, a single intraperitoneal injection of 107 Landschutz ascites cells was used to stimulate microvascular proliferation in the gastric mesentery or omental (Landschutz cells were first irradiated to prevent tumour formation). Capillary endothelial cells and their projections were stained using a peroxidase conjugate of the plant lectin Dolichos biflorus agglutinin.
Observed in whole mounts 30 microns in thickness, blind ending processes or 'sprouts' were seen to arise from omental capillaries. After tumour cell stimulation, the mean number of capillary sprouts per omentum increased from 36.7 to 240.3 (P = 0.0002). Concurrent heparin administration produced an exaggerated sprout response (mean 396.9, P=0.0288), while vascular sprouts were almost abolished by i.p. hydrocortisone ( The application of 31P NMR to the study of living cells has provided a non-invasive monitoring of cell energetics and offers a method for observing the effects of radiation on metabolism of tumours.
31P NMR can be used to determine the relative concentration of ATP, creatinine phosphate (PCr), inorganic phosphate (Pi) and several other phosphorated compounds such as (PME, PDE, DPDE). In addition, tissue pH can be calculated from Pi chemical shift.
We have used 31P NMR to study the metabolic changes related to hypoxia and have characterised the spectral changes occurring during recovery from hypoxia. There was a fall in ATP levels with concomitant increase in inorganic phosphate levels during hypoxia and these changes are almost completely reversed during recovery from hypoxia.
Following irradiation with photons and neutrons, the pattern of recovery from hypoxia differs. The irradiated HT29 cells showed an increase in Pi/ATP, PM/ATP and also the value of Pi, with maximum effect occurring after 3h. These changes are more marked following neutron irradiation and the increased Pi/ATP ratio persists after recovery. The significance of these findings requires further investi- Cancer, 56, 279 (1987) Cellular recovery from radiation damage has often been demonstrated using the split-dose experiment and the results interpreted using the multi-target model of radiation effect. This model predicts that once the fraction dose used in a split-dose experiment is off the shoulder of the survival curve, then recovery will remain constant. In contrast the more widely used linear-quadratic model (LQ) predicts that recovery will increase steeply as an exponential function of dose squared, at a rate determined by the B-component of the LQ equation.
To test these predictions we have performed split-dose experiments on four human tumour lines of widely differing radiosensitivity. The pattern of the results follows that predicted by the LQ model suggesting that the B-component of that model may be used as a measure of cellular recovery.
The most surprising result, however, is that our data shows that recovery capacity increases with increasing radiosensitivity. This is opposite of what is expected since it is usually accepted that cellular radioresistance is at least partly due to increased cellular recovery capacity. In addition, the data throw doubt on the common assumption that cells which have very steep radiation survival curves are recovery deficient. after explanation, using any sequence or dose required. Results are analysed as reduction in growth area relative to the untreated control. Growth is confirmed using autoradiography or Kl 67 antigen (Dako) and the epithelial nature of the culture is confirmed using cytokeratin immunocytochemistry.
Results using bleomycin + radiation on oesophageal normal and tumour tissue or cisplatin+radiation on bladder normal and tumour tissue suggest tumour cytocidal results may be optimised by the concurrent application of a clinically equivalent chemotherapy dose with a small single radiation dose. This reduced tumour cell growth to zero over a four week period after treatment, while sparing the surrounding normal tissue. Higher drug or radiation doses produced equal cytotoxicity in normal and tumour explants.
The technique has potential for predictive tumour therapy and clinical trials are in the process of being set up.
New Approaches to Diagnosis and Treatment majority needing palliation. Low power interstitial laser hyperthermia offers a means of producing localised thermal necrosis of predictable nature and extent in these tumours without the need for resection, and which heals safely.
Light from a low power Nd-YAG laser is transmitted via a 200 m fibre which is inserted in the centre of the target organ. With a single fibre, lesions up to 1.6cm (in rat liver) and 1.6 cm (in canine pancreas) in diameter can be produced with 1 W for 670-1,000 sec which heal safely, although higher powers (2W) can cause lethal pancreatitis. Using multiple (4) fibres activated simultaneously (1.5W for 670 sec per fibre) in liver, larger lesions of overlapping areas of thermal necrosis can be made, which measure 3.5 x 3 x 2.7 cm and heal by fibrosis and regeneration, but take 5-6 months to do so. In the pancreas with multiple fibres (1 W per fibre for 1,000 sec) inflammatory areas 6 x 2 cm can be produced that heal by inflammation and fibrosis by 3 months. Hyperamylasaemia is seen, but little clinical pancreatitis. Ultrasound has been used to insert and place fibres and to monitor accurately the evolution of the thermal damage.
Although not yet proven, it is likely that necrotic tumour will heal in a similar manner to necrotic normal tissue in these organs, so making this technique potentially valuable for in situ necrosis of these difficult tumours, particularly as it may be possible to match the extent of laser necrosis to the extent of tumour spread with ultrasound control. 131I-MIBG targetted radiotherapy in Yorkshire Meta-iodobenzylguanidine (MIBG) is a synthetic molecule taken up by adrenergic neuro transmitter vesicles. Labelled with 13lIodine in 18.5 MBq doses it is used for scintigraphic imaging of neurectodermal tissues and tumours. We report 4 cases in whom therapeutic doses were used as 'targeted radiotherapy'.
Patient 1, aged 11, had metastatic nodal neuroblastoma 4 years after primary treatment. Two patients had neuroblastoma persisting despite conventional treatment (patient 2, aged 4, in marrow, and patient 3, aged 5, in primary abdominal site and bone). Patient 4, aged 15, had inoperable right adrenal paraganglioma with hypertension.
After thyroid blockade 74 MBq tracer doses were used to estimate therapeutic doses, which were given as 45min i.v. infusions of 3.7, 3.3, 2.8 and 5.6 GBq respectively, requiring admission to a designated side ward for radiation protection purposes for one week. Whole body scan and static scintigrams were obtained from days 3-7 and weekly for four weeks enabling whole body and region of interest clearance curves to be plotted. Nausea was seen in patients 3 and 4 whose primary sites were adjacent to liver, but no major treatment related side effects were seen. Patient I showed tumour size reduction of more than 50% for five weeks, 2 and 4 showed no response, 3 advancing disease.
Work is continuing on the biological behaviour of 1311_ MIBG in children to allow increased tumour doses to be given without excessive whole body dose. A UKCCSG Study is now open for children with advanced neuroblastoma. The major source of oestrogen production in postmenopausal women is by the aromatisation of circulating androgens in extra-adrenal sites. The aromatase inhibitor aminoglutethimide has a 25% response rate as second line hormonal therapy in advanced breast cancer but its usefulness is limited by toxicity, particularly in the elderly (Hum. Toxicol., 6, 227 (1987) ).
4-OHA is a more potent specific aromatase inhibitor which has been shown to be active in breast cancer although the optimum dose is unknown (Cancer Res., 47, 1957 (1978 Eighty-one consecutive patients referred by one surgeon (HE) following lumpectomy for breast cancer, and whom received post-operative radiotherapy under the care of one radiotherapist (RHP), were considered for cosmetic result and morbidity assessment. All patients received 4,840cGy in 22 fractions to the breast and axilla, 5,940 cGy in 27 fractions to the supraclavicular nodes and a 2,000cGy boost to the primary site. Cosmetic results were quantified on a four-point scale for telangiectasia matchline effect, fibrosis and the doctor and patient's overall assessment. The surgical scar was also examined and the morbidity was assessed by shoulder abduction, upper and lower arm mid-point circumference, and by pain in the breast, axilla and arm.
Forty-eight patients were assessed at a mean of 67.4 months from completion of radiotherapy (range 54-98 months), whilst 33 were non-assessable due to death, local recurrence or were lost to follow-up. Telangiectasia and fibrosis were slight or absent in 45 and 36 respectively and moderate in the remainder. A matchline effect was not observed in any patient. The surgical scar was not apparent in 11, apparent in 35 and there was major tissue loss in 2. In no case was there considered to be a serious distortion of the breast. There was no significant difference in the range of shoulder abduction or arm circumference between the treated and untreated sides. One patient reported severe pain in the arm, none did for the breast and axilla. We conclude that the long-term cosmetic appearance and morbidity suffered following lumpectomy and radical radiotherapy is highly satisfactory. Flow cytometry is a convenient way of assessing tumour ploidy, but recent studies using this technique have cast doubt on earlier reports that ploidy determined by static cytometry is related to prognosis in breast cancer. To assess possible insensitivity of the automated method, we checked results of flow cytometry by simultaneous static cytometry in patients with pre-invasive breast cancer. Cell suspensions obtained by enzymatic disaggregation of 65 in situ carcinomas of the breast from the Nottingham breast clinic were stained by the Schiff reagent or diaminodio-2-phenylindoldichloride (DAPI) and DNA content measured by microdensitometry (static cytometry) and flow cytometry respectively. Breast cancer response to tamoxifen cannot be predicted reliably from oestrogen receptor status. Activity of tumour aglycerol phosphate-dehydrogenase has been reported to increase following tamoxifen. We investigated the effect of tamoxifen on activity of this and other enzymes involved in lipid biosynthesis: ca-glyceraldehydephosphatase-dehydrogenase and malic enzyme. Changes in cellular DNA content and thymidine kinase, an enzyme of DNA synthesis under oestrogen control, were also monitored.
Needle biopsies of primary breast cancer were assessed for histology, ploidy and enzyme activity before and 6 weeks after commencing tamoxifen. Tumour response was assessed by UICC criteria.
There was a significant reduction in thymidine kinase activity from 5.87+0.95 to 1.98+0.41 Umg-i protein (P<0.001, paired t) in 10 patients whose disease did not progress over a mean of 4.6 months. In contrast, activity increased from 3.43+1.43 to 3.95 + 1.52 U mg protein in 5 patients whose disease progressed (x2, P < 0.02). Neither treatment or tumour progression were related to changes in the other enzymes studied nor was response related to aneuploid (n = 14) or diploid (n = 1) DNA content.
Tamoxifen response was not related to activity of the enzymes of lipid metabolism tested in this study, however, oestrogen sensitive aspects of DNA synthesis, of which thymidine kinase is an example, appear more rewarding. In a phase II study with 22 patients, advanced metastatic breast cancer was treated with prolonged continuous infusion of mitozantrone (2mg day-1 x 14 days). Although the dosage regime of the continuous infusion was empirically derived, response rates were encouraging (CR =26%, PR=26% at 6 months).
We have carried out pharmacokinetic studies with some of these patients and have compared pharmacokinetic parameters obtained in continuous infusion regimes with those reported for traditional bolus or rapid infusion regimes. Pharmacokinetic parameters will also be related to clinical response/toxicity with the long-term objective of optimising drug dosage in continuous infusion schedules. A solid-phase extraction procedure and a sensitive HPLC assay were developed and validated to determine mitozantrone in plasma. The limit of detection was 500pgml-1.
The mean steady-state mitozantrone plasma level was 1.81 ngml-I (range 1.13-4.39, =6) and the mean area under the curve (AUC) was 0.517,ug.hml-1 (range 0.35-0.74yug.hml-1). This compares with peak plasma levels of 683 ng ml - (Van Belle et al., Cancer Chemother. Pharmacol., 18, 27 (1986) ) and AUC values of 1.45 pug.h ml-1 (Ehninger et al., Investigational New Drugs, 3, 109 (1985) ) reported for bolus regimes (14mgm 2 over 30 min). Our The mean saturation index (ratio of stearic acid to oleic acid) of rat erythrocytes was 2.0 + 0.3 in rats receiving normal saline and 1.09+0.28 in the NMU group (P<0.001).
These data indicate that iodostearic acid inhibits tumour development in rats. In addition, the onset of tumours is associated with a fall in the saturation index of rat erythrocytes. During the 3 year period in which we have been running a specific clinic for follow-up of colorectal cancers, 12 patients have presented to our unit with intestinal obstruction and signs of perforation (group 1). In this series we have compared the clinical course of these patients with that of patients who sustained inadvertent colonic perforation at operation (group 2). Mean age and sex distribution was similar in the 2 groups, as was Dukes' staging and degree of differentiation. However, a single patient with carcinoid of the appendix presented with peritonitis. Left sided tumours predominated in both groups but rectal tumours, which accounted for the vast majority of those undergoing operative injury (65%), were notably absent from those presenting with peritonitis, presumably due to the capacious nature of that portion of the bowel. Mean follow-up of group 1 was 27 months (1-124 months) and of group 2 was 56.5 months (11 135 We have followed-up all colorectal cancers in a specific clinic over the last three years, and during this period 24 patients had postoperative intra-abdominal or intrapelvic sepsis (19 with clinically evident sepsis and 5 with radiological evidence of anastomotic leakage). The subsequent clinical course of these patients is compared with that of an age/sex and stage matched cohort (N= 25), who did not have evidence of postoperative sepsis. Mean age of group 1 was 65.2 years and of group 2, 66.7 years. Left sided tumours predominate in both groups, with a slightly higher proportion of right sided tumours in group 2 than in group 1. Mean follow-up of both groups exceeded 2 years (group 1: 149.5 months, group 2: 38.4 months). Twenty-one patients in group 1 and 23 in group 2 are alive and available for follow-up, 2 cases from each group having died from carcinomatosis and a further 1 from group 1 having died from cardiovascular disease. However, overall recurrence rates differ markedly. In group 1, 5 patients have had evidence of local or distant disease (21%), whereas 10 patients from group 2 (40%) are affected. Although this does not achieve statistical significance, there would appear to be an important trend towards improved recurrence rate with postoperative sepsis. This might conceivably arise from either a general non-specific stimulus to the immune system, brought about by infection or by the occurrence of an unfavourable environment for implantation to take place.
Gastro-intestinal Tract Malignancy
Cancer in Crohn's disease after diversionary surgery: A study of the crypt cell production rate given at 1 cm from the sources using the Selectron oesophageal applicator. A high incidence of tumours has been reported (Greenstein A reduced ratio of RBC stearic to oleic acid ratio has been et al., Am. J. Surg., 135, 86 (1978) ) after diversionary proposed as a highly sensitive marker of CRC. However, surgery for Crohn's disease which is related to the duration objections have been raised about matching of patients and of Crohn's disease rather than that of the bypass. To assess the role of dietary fat has not been previously assessed. whether this high incidence is due to changes in colonic Using gas liquid chromatography, the fatty acid profile in cytokinetics after bypass, the rectal crypt cell production rate RBCs and adipose tissue was determined in 49 patients with (CCPR) has been assessed in patients with defunctioned CRC and 49 age and sex matched controls. In the CRC Crohn's colitis (DCC) (n=9) and a control group (DC) for a group there were marginally increased levels (mean s.e.m.) of non-inflammatory condition (n=6). The mean duration of stearic acid (18.1 + 0.4 vs. 17.2 + 0.3, P = 0.06) and oleic acid Crohn's disease was 58 (12-134) months. The mean diver-(20.3 + 0.4 vs. 19.0 + 0.4; P = 0.06) and decreased arachidonic sionary period was 9 (2-16) months for Crohn's disease and acid (22.0+0.4 vs. 23.4+0.6, P=0.04). There was no dif-3 (1-8) months for controls. Results were compared with ference in the RBC stearic to oleic acid ratio between the controls (C:n=21) and patients with ileal Crohn's disease two groups (0.9+0.02 vs. 0.91+0.01); there was no correla-(CD:n=9) and Crohn's proctitis (CP:n=15) who had not tion of this ratio with the Dukes' staging. The polybeen defunctioned. unsaturated/saturated (P/S) ratio of dietary fats and adipose tissue was correlated in both groups (P<0.001). The RBC P/ DCC DC C CD CP S ratio was also correlated with the dietary P/S ratio in the CCPR+s.e.m. 2.5+0.4 2.9+0.6 3.2+0.5 4.0+0.7 2.8+0.7 cancer group (P<0.01).
(cells crypt lh 1)
In conclusion, small differences of RBC fatty acids in CRC are linked to dietary fat. The RBC stearic to oleic acid This study has failed to demonstrate anv chane in the was not diagnostic of CRC in this study cellular proliferation rate in the excluded colon after a disease duration of 5 years and a diversionary period of 9 months. It suggests that the risk of carcinogenesis in bypassed bowel is not due to changes in cell kinetics. There were 329 operations performed (AR: 91, AP: 238). Serious complications were recorded in 22.2% of patients (AR: 28.6%, AP: 19.7%). The operative mortality was 14.0% (AR: 17.6%, AP: 12.6%). Both morbidity and mortality were related to the age of the patient. Following anterior resection the operative morbidity and mortality was related to the distal clearance of the tumour. There was no correlation between the grade of the surgeon and morbidity or mortality.
Crude 5 year survival was 27.6% overall, ranging from 68.1% for Dukes' A tumours to 5.5% in patients with distant metastases (AR: 81.2% to 0%, AP: 61.3% to 9.1%). Survival was not related to the distal clearance (AR) or distance of the tumour from the anus (AP). Local recurrence occurred in 27.4% (AR: 30.8%, AP: 26.1%). The mean interval from operation to development of local recurrence was 18 months (AR: 14, AP: 19). The mean interval from diagnosis of local recurrence to death was 11 months (AR: 12, AP: 10).
Most reports have been from teaching centres or of a single surgeon's experience, and have shown lower operative mortality and better survival rates. Our results therefore give no cause for complacency. A retrospective analysis on 75 patients treated at the Royal Marsden Hospital between 1958 and 1986 showed that 29 presented with Lyons T2 tumours and 27 Lyons T3. Twenty patients (26.6%) had inguinal nodal metastases and 3 systemic dissemination. Definitive treatment was radiotherapy in 55 patients, 46 of whom received a radical dose of 60 Gy/ 30 * /6 weeks, or NSD equivalent. Four of these had combined modality treatment with SFU and mitomycin-C. Of 20 patients treated by surgery 9 received pre-or post-operative radiotherapy. The median follow-up of survivors was 49.8 months. The actuarial case specific survival at three years was 55% and this was adversely influenced by increasing stage and histological grade. In the radiotherapy group 72.2% (13/18) of TI, T2 no patients were controlled, and 3 of 5 relapsing patients were salvaged by surgery. Five of eight patients who developed distant metastases also had uncontrolled primary tumours. Six of 20 (30%) patients treated by surgery recurred loco-regionally and none were salvaged by radiotherapy.
It is concluded that radiotherapy alone is effective treatment for small epidermoid anal carcinomas, and has the advantage of preserving anal continence. More advanced tumours probably require combined modality treatment.
patients showed renal toxicity, or suffered symptomatic neurotoxicity or pulmonary toxicity. Seventy-eight cycles in 22 patients have been studied for haematological toxicity. No cases of WHO grade IV toxicity, septicaemia or haemorrhage have occurred. In only 3 cycles did the nadir platelet count fall below 50 x 1061-1.
We conclude that the toxicity of this combination is minimal and that there can be further escalation of dosage in patients with high GFR. Patients presenting with large (>5 cm) abdominal metastases from malignant non-seminomatous germ-cell tumours may be at particular risk of long-term renal damage from the combined effects of ureteric obstruction and cisplatin chemotherapy. Renal function (51EDTA clearance) and the presence of hydronephrosis (HN) and/or renal cortical atrophy were studied prior to and following chemotherapy in 114 patients to identify potential risk factors for late renal damage. Low EDTA clearance at presentation was significantly more common in the presence of HN (21/40 vs. 8/74 without HN, P<0.01). In the absence of HN patients treated with cisplatin retained acceptable renal function at the completion of chemotherapy (clearance 102mlmin-1). Of 32 patients with HN receiving cisplatin, 6 had renal atrophy at presentation, and 6 developed late atrophy. The development of atrophy and poor renal function at the end of chemotherapy were both associated with failure to improve EDTA clearance by at least 10% after one month of treatment, and with presenting clearances below normal. By contrast 7 patients with HN receiving carboplatin showed an overall improvement in renal function (95 124mlmin-1) and none developed renal atrophy. Thus hydronephrosis and low EDTA clearance at presentation, together with failure to show an early improvement in renal function (through relief of obstruction) predict for late renal damage, which may be avoided by the use of carboplatin or possibly by the use of ureteric stenting in bad risk patients. In May, 1986 we commenced using the combination of carboplatin 350mgm-2 day 1, etoposide 120mgm-2 days 1, 2 and 3 i.v. with cycles repeated after 21 days, with bleomycin 30mg i.m. weekly to a total dose of 360 mg. Subsequently the dose of carboplatin has been increased to 750mg in patients with glomerular filtration rate (GFR) greater than 90mlmin-1, and later to 900mg where GFR exceeded 120 ml min-and initial platelet count exceeded 200x1061-.
Genito-urinary Cancer
No major toxicity has been encountered. Nausea Cisplatin administration is known to cause renal tubular defects. A retrospective survey of 165 patients (aged 11-70 years) treated in Edinburgh (1978 Edinburgh ( -1987 with various cisplatin regimens has now been completed; all patients received mannitol and intensive hydration but no routine magnesium supplementation. Fifteen of 165 (9%) developed asymptomatic systemic acidosis (plasma bicarbonate <21 mmol -1) and in 10 patients (6%) mild acidosis persisted. There was no correlation between bicarbonate and Mg levels with cumulative cisplatin dosage (range 100-900 mg m-2). Plasma potassium levels remained unchanged.
The majority of patients develop hypomagnesaemia while a minority develop tubular acidosis. The incidence and severity of incomplete renal tubular acidosis is under investigation. Between April 1984 and December 1987, 35 patients with seminoma were referred.
All were investigated with serum markers (AFP and BHCG) lymphogram, CT scan of abdomen and ultrasound of testes.
Two were excluded because of elevated alpha foetoprotein. Of the 28 stage 1 patients, 25 were considered to be of good prognosis and received no adjuvant radiotherapy.
Of these, 3 patients have relapsed (12%) after 5, 6 and 6 months respectively. Mean follow up is now 26 months (6-50 months).
All patients remain alive and disease-free. The relapse rate with stage 1 seminoma treated by orchidectomy alone and careful observation may be lower than stage 1 teratoma and may be a safe alternative to adjuvant radiation.
Dose of intravesical chemotherapy J.R.W. Masters
Institute of Urology, University College, London, UK.
The response of tumours to systemic chemotherapy is proportional to the dose rate achieved. Dose rate usually is calculated as the area under the plasma drug concentrationtime curve (AUC or C x T). In contrast, this concept is not used for intravesical chemotherapy. Instead, it is the weight of drug instilled into the bladder that is considered to be the dose. Thus, a 60mg instillate of ThioTEPA gives a twofold higher dose than a 30mg instillate, regardless of the volume of fluid or the period of exposure. The drugs usually are dissolved in a corresponding volume of solvent, the 60mg in 60ml and the 30mg in 30ml, giving a twofold difference in 'dose', but at identical concentrations of 1 mg ml-1. It is probable that the response of superficial bladder cancer to intravesical chemotherapy also is proportional to the drug concentration and period of exposure (CxT). Many published studies of intravesical chemotherapy record neither the drug concentration nor the period of exposure, only the weight of drug, and consequently optimum doses have not been calculated. If CxT were used to calculate the dose, intravesical chemotherapy could be made safer, cheaper and more efficient, as less drug would be needed to achieve the same dose. By reducing the volume of instillate to the minimum quantity required to cover the tumour and urothelium, the patient may be able to tolerate the therapy for a longer period, thus further increasing the dose rate. These measures could increase the success rate of intravesical chemotherapy. Twenty-two patients with advanced metastatic carcinoma of the prostate previously managed with first line hormone therapy (orchidectomy, LHRH analogue or diethylstilboestrol) have received megestrol acetate 160 mg daily, at disease progression. Patients have been followed up for a period of up to 36 months with a minimum follow-up of 6 months.
Twenty-one patients are evaluable for toxicity and response. The treatment was well tolerated with minimal morbidity. Two patients reported excess weight gain and 2 developed exacerbations of congestive cardiac failure which stabilized with reduction in dosage of megestrol to 80mg daily. Eight patients (38%) reported subjective improvement in their symptoms. An objective response as assessed by serial rectal examination, bone scanning, X-rays and prostatic acid phosphatase assay according to the criteria of the NPCP was seen in 6 patients (28%). There were no complete or partial responses, all responses being stabilization of disease of 6-12 months duration (mean 40.3+12.8 weeks).
We have reviewed the controversial role of second line hormonal measures in advanced carcinoma of the prostate and conclude that megestrol acetate has a useful role and is as effective as other measures with the advantage of minimal morbidity. To assess the efficacy of local treatment of carcinoma of the prostate *at our institution we carried out a retrospective analysis of patients treated for localised carcinoma of the prostate (TO-4, NX, MO) between January 1976 and December 1985. Following initial treatment of obstructive symptoms with either transurethral resection of the prostate or retropubic prostatectomy the patients were then allocated to either radical radiotherapy, orchidectomy, or diethylstilboestrol. This is an on going analysis which will include over 300 patients but we present an interim report of 43 patients (mean age: 66 years, age range: 47-79 years) treated by radical radiotherapy (6,000cGy in 30 daily fractions over 6 weeks), and 30 patients (mean age: 72 years, age range: 53-84 years) treated by bilateral subcapsular orchidectomy or diethylstilboestrol.
Local tumour control was significantly better in the radiotherapy group (76%) compared to the hormone group (45%) although there was no significant difference in the time to first systemic disease progression overall. Probability of local control decreased with poorly differentiated tumours and T3-T4 tumours fared worst in both groups.
Radiation therapy was tolerated well with a 9% late complication rate including proctitis, tenesmus, and bladder neck contracture. Carcinoma associated antigen (CA-50) is a tumour associated carbohydrate antigen, defined by the monoclonal antibody C50, which has been raised against a colorectal adenocarcinoma cell line. The aim of this study was to assess whether CA-50 can differentiate patients with urological carcinomas from normal subjects and those with benign disease. A radioimmunoassay was used for the detection of CA-50 in the serum of 50 normal subjects, 86 patients with benign disease and 104 patients with urological carcinomas. Serum levels in all 50 normal subjects and 83 of 86 patients (97%) with benign disease were <17 U ml-1, while 49 of 104 patients (47%) with carcinoma had levels > 17 U ml-1. Thc sensitivities for prostatic, bladder and renal carcinomas werc 43%, 62% and 47% respectively. In patients with prostatic carcinoma, the sensitivities were 0% for well differentiated carcinomas, 33% for moderately differentiated carcinomas. 67% for poorly differentiated carcinomas and 71% formetastatic disease. The sensitivities for non-invasive and invasive bladder carcinomas were 42% and 89% respectively. Therefore this test may prove useful in the diagnosis of patients with urological malignancies. monoclonal antibodies to tumour associated antigens. Blood and urine Yttrium-90 activities were monitored for 5 days after treatment. The non-specific radiation dose to the peritoneal cavity was measured by lithium fluoride thermoluminescent dosimetry. Yttrium-90-labelled antibodies were absorbed from the peritoneal cavity into the systemic circulation with 20% of the injected dose at 40 h. Bone marrow suppression is the dose limiting factor with moderate toxicity after 15 cCi Y-90-labelled monoclonal antibody. The estimated radiation dose to the marrow from the circulating Yttrium-90-labelled antibody was < 50 cGy. Bone marrow irradiation from unchelated Yttrium-90 absorbed onto bone, may account for the discrepancy between the estimated radiation dose to marrow and observed toxicity. Although this was primarily a phase I study we observed a partial response in 1 out 5 patients with tumour nodules <2 cm in diameter.
Head and Neck Cancer
Chemotherapy in cervical carcinoma
S. Powell
For the London Gynaecological Oncology Group, UK.
The poor survival of FIGO stage Ilb, III, IV and early stage node positive cervix cancer has led to interest in chemotherapy in addition to standard methods of local treatment. We studied four chemotherapy regimes in patients with recurrent cervix cancer.
One hundred and twenty-five patients received treatment: (1) 41 received single agent ifosfamide (1.5gm-2, days 1-5); (2) 39 received ifosfamide (as (1)) and cisplatinum (50 mg m-2, day 1); (3) 28 received cisplatinum (20 mg m -2, days 1-3), etoposide (120mgm 2, days 1-3) and bleomycin (15mg, day 1); (4) 11 received cisplatinum (as (3)), methotrexate (100mg, day 1) and bleomycin (15mg, day 1); (5) 6 others received cisplatinum alone or in other combination. Treatment schedules were repeated 3 weekly.
Three patients in (1) and six patients (3) had adenocarcinoma. None of these responded and were excluded. Response rates were: (1) 33% (12/36); (2) 38% (12/31); (3) 40% (8/20); (4) 30% (3/10) and (5) 60% (3/5). Comparative haematological, renal and neural toxicity will be presented.
When chemotherapy was given neo-adjuvantly, response rates were higher: treatment (3) 67% (6/9) and treatment (4) 57% (4/7). Active agents have been found for squamous carcinoma of the uterine cervix, but combination chemotherapy has not led to significantly enhanced efficacy. In previous studies 16% of supine and 26% of prone pelvic treatments using skin marks showed a lateral shift of 10mm or more.
Fifteen patients receiving pelvic irradiation were studied to see if reproducibility could be improved by using lateral alignment lasers. Films were taken at the initial treatment simulation and on 4 subsequent occasions. Patients were set up initially without and then with the use of lateral lasers and films taken for comparisons.
Also, using a body phantom, we have measured shifts occurring with differing degrees of lateral rotation.
In comparison with our initial study we find that the magnitude and frequency of lateral shift errors is less, and that this is further reduced by the use of lateral lasers.
Clinically significant caudo-cephalic shifts of up to 2cm are seen and we are currently studying means of reducing these errors.
Our experience will be presented and discussed together with recommendations for optimising treatment delivery. Nineteen patients were treated and 6 developed unexpected lung toxicity 8-10 weeks after start of chemotherapy. The pneumonitis was fatal in 5 patients. This occurred at bleomycin doses < 50 U m-2 and cyclophosphamide < 1,875 mgm-2.
Thirty-five percent incidence of apparent drug induced pneumonitis following low doses of bleomycin in evaluable patients suggests an increased susceptibility to drug induced pulmonary damage in patients with non-Hodgkin's lymphoma. malignant disease. A proportion (25%-40%) of patients display persistent thrombocytopenia after ABMT. An autoimmune basis for this delay in recovery of peripheral cell counts has been postulated and a high incidence of cell specific antibodies to platelets (52%) and neutrophils (65%) has been detected in the. early post-graft platelet count recovery post allogenic bone marrow transplantation. Potential factors of relevance to the formation of autoantibodies include the patient's underlying malignancy, pregraft chemotherapy and/or radiotherapy, in vitro damage to stem cells during graft storage, the engraftment procedure, insufficient numbers of inadequately functioning T-lymphocyte suppressor cells in the early post-graft period and post-graft blood component transfusions. The use of recombinant GM-CSF to accelerate the rate of recovery of peripheral blood counts post ABMT may be associated with the development of platelet-associated immunoglobulins. Prolonged thrombocytopenia post ABMT increased the patient's risk from bleeding, either spontaneous or associated with sepsis, and increases the risk associated with prolonged blood component transfusion requirement. The administration of intravenous immunoglobulin is an established modality of therapy in idiopathic thrombocytopenic purpura. We discuss the format of a pilot study to ascertain whether intravenous immunoglobulin therapy can accelerate delayed platelet recovery post ABMT and some initial data from one such study. The aim of this project was the study of the role of high dose gallium (Ga-67) scanning in the assessment of mediastinal Hodgkin's disease (HD).
Comparison of thoracic CT and Ga-67 single photon emission computed tomography (SPECT) images was undertaken using high dose Ga-67 in patients with biopsy proven HD at presentation and after treatment.
Sixteen patients with HD had pre-treatment CT scan and Ga-67 SPECT studies. As reported elsewhere at this meeting, we have found upper hemi-body irradiation (UHBI) to be an effective, well tolerated therapeutic modality in advanced multiple myeloma. This procedure involved the administration of a median dose of 7.5 Gy from a slow cobalt source to the upper body in 35 patients, 18 of whom also received lower HBI. In this series, the only procedure related death that occurred was attributed to radiation-induced pneumonitis. Three other patients were also diagnosed as having post therapy pneumonitis, 2 of whom required and responded to oral corticosteroid therapy. This gave a total incidence of overt symptomatic pneumonitis of 14% following UHBI in this series of heavily pre-treated multiple myeloma patients. In order to delineate the extent of therapy-induced pneumonitis, we have begun to do baseline lung function tests before the UHBI procedure followed by sequential tests in the post therapy period. (Capanna et al., Cancer, 54, 177 (1984) Ten patients with soft tissue sarcomas of the limb or limb girdle have been re-irradiated on 12 occasions for local recurrence following previous limb conserving treatment. The histological types were: Liposarcoma (5), fibrosarcoma (2), malignant fibrous histiocytoma (1), rhabdomyosarcoma (1), synovial sarcoma (1) with 6 tumours being of high grade malignancy. Retreatment was given with palliative intent in 5/12, and with curative intent following marginal excision in 7/12, at a median time of 15 months after initial treatment (range 8-324 months). Initial radiotherapy was given at doses ranging from 1,362-1,941 ret (median 1,650 ret, dose range 33-60Gy) whilst for retreatment the curative group received a median 1,768ret (dose 33-60Gy) and the palliative group a median 1,303ret (dose range 12-5OGy). Initial local control was achieved in 7/10 of patients and eventually following 8/12 courses (median duration of local control 9 months); one patient being controlled by further surgery and radiotherapy. Three patients died from metastatic disease with local control at the primary site. Early toxicity was not severe with most desquamation in 2/12. Late toxicity was severe in 1 case following the third treatment with late radionecrosis requiring amputation. Moderate oedema and diminished limb function were seen in 2 cases. Re-irradiation of the limb and limb girdle appears to be well tolerated and offers an alternative to amputation for local relapse following previous radical multimodality therapy. Survival parameters were measured from the time of diagnosis. Overall 10 year actuarial survival was 50% in all cases with an overall disease free survival of 60%. Considering only death from meningioma, the corresponding cause specific actuarial survival was 65%.
Prognosis was related to the extent of initial surgical resection. Of those who underwent subtotal tumour resection with subsequent minimal residual disease, the 10 year actuarial survival was 70%. Where only partial resection was possible the corresponding survival was 60% and in inoperable patients treated by radiotherapy alone 45%. Eighteen patients underwent complete resection of disease prior to irradiation with a resultant 10 year survival of only 20% owing to the high incidence of adverse histological subtypes in this group which included malignant meningioma, all of whom died within 5 years of diagnosis. These differences are statistically significant.
Performance status at the time of referral for postoperative radiotherapy was measured retrospectively using the Karnovsky scale. Patients with a performance rating of 80-100 had a 70% 10 year survival, whereas those with a score of less than 80 had a 40% survival. The difference is statistically significant.
Patients undergoing complete surgical resection and not requiring adjuvant irradiation have an inherently good prognosis. It is therefore not possible to select an appropriate control group; however, the long term survival of irradiated patients in this series supports the benefit of postoperative radiotherapy in patients with residual disease.
Conference Lecture The rationale for giving radiotherapy as a series of small doses instead of a single treatment has been developed long after it became common clinical practice. It is not at all clear whether the current 2.0-2.5Gy per day for 4-7 weeks is optimized.
Recent experimental data have emphasized that differences in the response to repeated treatments exist in late reacting tissues compared with acutely responding tissues and tumours. It is therefore inappropriate to select new therapies based on therapeutic differences between skin and tumours. The relevant comparisons must be made with slowly proliferating tissues, e.g., lung or kidney.
The experimental data highlighting the differences in repair capacity and in regenerative capacity will be reviewed. The influence of reoxygenation and redistribution around the cell cycle between fractions will also be discussed.
These concepts have led to a new clinical regime -CHART -at Mount Vernon Hospital, involving 36 fractions given three times a day, with minimum interfraction intervals of 6 h and no break for the weekend. The biological basis of this trial and the criticality of the different elements will be presented. IGuy's Hospital, 2University College Hospital and 3Institute of Neurology, London, UK.
Bob Champion Cancer Trust Lecture
We have evaluated JM8 and JM9 in the treatment of high grade glioma, firstly in a phase II clinical study and secondly, by in vitro chemosensitivity assay.
Fifteen patients were treated (7 grade III and 8 grade IV) with JM8 or JM9. All had relapsed after surgery and either radiotherapy alone (3 pts) or radiotherapy and chemotherapy with procarbazine, CCNU and vincristine (12pts). Median age was 45 yrs and ECOG score 2. Chemotherapy was JM8 400 mgm 2 (10 pts) or JM9 300 mgm-2 (5 pts) given every 4 weeks; response was assessed by CT scan: The response rate was 2/15 (1 response to JM8 and 1 to JM9). Myelosuppression was considerable and 3 patients developed grade IV neurotoxicity.
Chemosensitivity was assessed in 8 short-term cultures derived from biopsies in a separate group of patients with malignant glioma, by a 35 S-methionine uptake assay. The ID50s ranged from 0.02 to 3.7,ugml-' for JM8 and 0.008 to 2.8 ug ml -1 for JM9. There was evidence of cross resistance between the two agents, but no evidence of cross resistance with CCNU. The range of sensitivities observed for JM8 and JM9 were comparable to those observed for cis-platinum in earlier studies.
JM8 and JM9 have activity against high grade glioma both clinically and in vitro, but toxicity was significant in this group of poor prognosis patients. Further evaluation of JM8 should be in good performance status patients. It has been shown that administration of hydralazine to mice induces severe hypoxia in experimental tumours of various types. In principle, the induction of severe hypoxia in tumours by manipulation of blood flow can be exploited for enhancing the efficacies of some chemotherapeutic agents, including bioreductive radiosensitizers and alkylating drugs such as melphalan.
We have compared the efficacy of hydralazine and other established vasoactive agents including 5-hydroxytryptamine (5-HT), nifedipine and verapamil for their ability to increase the anti-tumour effectiveness of melphalan. Treating mice with hydralazine 15 min after melphalan results in an enhancement of , 3.0 for melphalan induced delay in growth of either the RIF-I or KHT tumours. Similar enhancements are achieved when hydralizine is given before melphalan. Administration of 5-HT also enhances tumour response but only when given after melphalan. Both hydralazine and 5-HT can induce close to 100% radiobiological hypoxia in the RIF-l and KHT tumours. In contrast, nifedipine has no effect on tumour hypoxia fraction at a dose (10mgkg-1) which nonetheless substantially increases the anti-tumour effectiveness of melphalan. Hydralazine can also produce up to a 10-fold increase in the sensitizing efficiency of misonidazole and RSU 1069 in the KHT tumour in mice. This is likely to be due to the vasoactive agent inducing close to 100% tumour hypoxia after irradiation and so allowing greater expression of the differential toxicity of the sensitizers towards those hypoxic cells surviving the radiation treatment. Other radiosensitizers have been combined with hydralazine and it was found that the sensitizing efficiency of etanidazole and Ro 07-9963 was not significantly improved by subsequent administration of hydralazine. There was a small (2-4 fold) improvement in the sensitizing efficiency of We propose that rational selection of hypoxic cell cytotoxins could be based upon enzymological characterization of the reductases present in a biopsy specimen. This will be facilitated by development of (1) conventional and flow cytometric assays for specific reductases, and (2) techniques for non-invasive identification of hypoxic cells in vivo.
Progress in these areas will be described. The potential for vasodilators to enhance bioreductive cytotoxicity in man depends not only on the development of bioreductives of low toxicity, but also on the ability of vasodilators to produce the necessary reduction in tumour blood flow without serious cardiovascular sequelae.
The physiol'ogical changes necessary to produce a fall in tumour blood flow are discussed with reference to a simple mathematical model incorporating the normal physiological responses to vasodilator therapy.
A study investigating the effects of single-dose hydralazine on tumour blood flow is discussed.
